{"id":"rivoceranib-apatinib","brandName":"Rivoceranib (Apatinib)","genericName":"Rivoceranib (Apatinib)","companyId":"jiangsu-hengrui-medicine-co-ltd","companyName":"Jiangsu HengRui Medicine Co., Ltd.","phase":"phase_3","status":"active","modality":"Small molecule","aliases":[],"developmentCodes":[],"firstApprovalDate":null,"firstApprovalCountry":null,"aiSummary":"Rivoceranib, also known as Apatinib, is a small molecule used in the treatment of various cancers, including gastric cancer, gastroesophageal junction adenocarcinoma, and metastatic colorectal cancer. It is being studied as an adjuvant therapy in patients with hepatocellular carcinoma (HCC) at high risk of recurrence after curative resection or ablation.","enrichmentLevel":3,"visitCount":0,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting VEGFR2, Rivoceranib reduces angiogenesis and tumor growth. This mechanism is particularly effective in treating various types of cancer.","oneSentence":"Rivoceranib (Apatinib) is a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor 2 (VEGFR2).","_ai_confidence":"high"},"administration":{},"safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Hypertension"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"}]},"trials":[],"indications":{"approved":[{"name":"Metastatic gastric cancer, Metastatic non-small cell lung cancer"}]},"commercial":null,"patents":[],"timeline":[],"rwe":[],"competitors":[],"ownershipHistory":[],"trialDetails":[],"genericFilers":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"labelChanges":[],"nice":null,"revenue":null,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}